• Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS
• Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a treatment for ALS via the accelerated approval process
• The briefing book includes new post-hoc analyses of data from completed clinical trials and addresses comments made by the FDA during a previous meeting in late 2023

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and protecting neuronal function to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), have revealed plans to submit a briefing book to the U.S. Food and Drug Administration (“FDA”) by July 13. This submission precedes a granted Type C interaction scheduled for the third quarter of 2024, aimed at obtaining FDA feedback on the potential pathway for a new drug application (“NDA”) for CNM-Au8 as a treatment for ALS via the accelerated approval process (https://ibn.fm/icmDr).

CNM-Au8, Clene’s primary therapeutic asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Neurodegenerative diseases often involve multiple pathogenic factors leading to neuronal death, with mitochondrial dysfunction and NAD+ decline being critical pathways. NAD+ is essential for cell survival and function. CNM-Au8’s catalytic mechanisms are designed to address the energy deficits, oxidative stress, and accumulation of misfolded proteins typical in many neurodegenerative diseases.

The briefing book includes new post-hoc analyses of data from completed clinical trials and addresses comments made by the FDA during a previous meeting in late 2023. In that meeting, Clene received guidance on the potential for accelerated approval. The briefing book provides additional analyses on the reduction of the neurofilament light (“NfL”) biomarker, a more comprehensive set of survival and functional benefit data, and further evidence of CNM-Au8’s mechanism of action.

Clene believes that these analyses collectively support the accelerated approval based on NfL reduction as a surrogate endpoint. Moreover, the company has included data to address the FDA’s request for more information on the relationship between CNM-Au8’s proposed mechanism of action and NfL reduction, as well as the link between observed NfL reductions and improved clinical outcomes in ALS patients, including survival rates.

The unique mechanism of action of CNM-Au8 is believed to provide neuroprotection and support remyelination in neurodegenerative conditions by: (1) promoting and maintaining beneficial metabolic and energetic cellular reactions in diseased, stressed, or damaged cells, (2) catalyzing the reduction of harmful reactive oxygen species (“ROS”), and (3) enhancing protein homeostasis through activation of the heat shock factor-1 pathway. This pathway helps reduce the cytotoxicity caused by misfolded and denatured proteins, which are common in neurodegenerative diseases.

CNM-Au8, used in combination with other treatments, has no known drug-drug interactions and aims to improve function and survival. Clinical trials for ALS have demonstrated its positive effects on both function and survival, as previously reported.

In clinical trials and Expanded Access Protocol programs for ALS, MS, and Parkinson’s disease, CNM-Au8 has been collectively used for over 500 estimated years without any reported safety concerns.

The neurodegenerative disease market size is estimated at $55.12 billion in 2024 and is expected to reach $77.82 billion by 2029, growing at a CAGR of 7.14% during the forecast period. This growth can be attributed to the increase in number of neurological disorder diagnoses, the growing awareness globally, and the lineup of products being developed for treatment (https://ibn.fm/t0wmc).

Further details on these new data analyses will be shared publicly later in 2024. Clene plans to publicly announce the FDA’s feedback following the completion of the Type C interaction.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Majority of surveyed businesses actively engaged in quantum computing anticipate significant returns on investment (“ROI”) from their quantum optimization efforts
• Survey also highlights a significant increase in quantum adoption, with 21% of respondents either currently employing or planning to integrate quantum technology into production within the next 12 to 18 months
• D-Wave has been named a finalist in the GameChanger Ambition category of the upcoming Technology Impact Awards (“TIAs”) by the BC Tech Association

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced the findings of a recent study it commissioned with Hyperion Research on enterprise quantum computing adoption plans. Notably, a majority of the surveyed businesses actively engaged in quantum computing anticipate significant returns on investment (“ROI”) from their quantum optimization efforts. The potential combined positive financial impact is estimated to reach approximately $51.5 billion (https://ibn.fm/WklRF).

The survey, conducted between May and June 2024, tapped more than 300 decision makers from enterprises across the United States and select European countries that are exploring quantum optimization of critical business processes within the next 12 to 18 months. Among the respondents, 290 indicated an intention to commit between $3 to $6 million annually toward quantum optimization initiatives, with anticipated benefits ranging from $60 to $65 million each year. This translates to a notable ROI of between 10 to 20 times the initial investment. The estimated total benefits of $51.5 billion for those companies surveyed underscores the significant potential of quantum optimization to drive substantial improvements and create value across various industries.

The survey also highlighted a significant increase in quantum adoption planning, with 21% of respondents either currently employing or planning to integrate quantum technology into production within the next 12 to 18 months. This marks a 50% rise in adoption plans compared to Hyperion Research’s 2022 report, indicating a growing recognition of quantum computing’s tangible business value.

Respondents identified enhancing business process efficiencies as the primary benefit of quantum optimization (24%), followed by revenue growth (20%) and fostering innovation (14%). Additionally, respondents recognized the potential of quantum computing to optimize finance-related operations (17%), supply-chain management (16%), and manufacturing (14%).

“In my view, the data is clear: quantum computing has arrived as a critical business imperative. Those who proactively embrace this technology and invest in optimization efforts stand to reap significant rewards,” said Dr. Alan Baratz, CEO of D-Wave. “The anticipated gains and ROI projections paint a compelling picture of a possible near-term future where quantum computing becomes a fundamental driver of business success.”

According to the survey, improvements in workload performance emerged as the most significant driver for organizations adopting quantum computing. The advocacy for quantum computing adoption extends beyond technical teams to senior management, reflecting an increasing enterprise-wide interest in leveraging quantum technologies. Furthermore, organizations are prioritizing enhancements to existing business processes rather than solely focusing on developing new quantum-based applications.

In addition, D-Wave recently was named a finalist in the GameChanger Ambition category of the upcoming TIAs by the BC Tech Association. The award recognizes companies that leverage their ambition to address significant challenges with innovative technology, aiming to make a substantial impact (https://ibn.fm/AsGAv).

“This finalist nomination means a tremendous amount to the technology team in our B.C.-based Quantum Engineering Center of Excellence. We are making amazing strides to advance the science of quantum computing as well as develop six generations of quantum computing systems and are honored to receive this recognition,” said Dr. Trevor Lanting, Chief Development Officer for D-Wave. “We are grateful to BC Tech for being a stalwart champion of innovation and for helping companies like D-Wave promote our talent around the world.”

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

• Considered intangible assets, patents offer a significant competitive advantage and value for companies
• Lexaria Bioscience views its growing patent portfolio as a solid foundation upon which to build future commercial partnerships
• The company recently announced the receipt of three new patents in the E.U., Canada, and the U.S.
• The issuance of the latest three patents grows Lexaria’s patent portfolio to 46 granted patents worldwide

Lexaria’s multi-patented DehydraTECH(TM) “drug delivery platform technology” offers proven increased bioavailability, enhancing the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of APIs. Strong patents covering this important technology are a critical factor for Lexaria.

A robust patent portfolio has always been a metric that investors use to judge a biotechnology or biopharmaceutical company. “A strong patent position is not only an important goal for a successful biotechnology business but also the primary asset by which a company will be valued during all stages of its development. Therefore, a patent portfolio must be as well designed and solidly constructed from the outset as all other aspects of the business,” a 2001 article conveyed (https://ibn.fm/OZA2n).

Not much has changed since the article’s publication, with a recent Forbes write-up observing that intangible assets, which include trade secrets, proficiency and expertise, trademarks, copyrights, and patents, accounted for 90% of the S&P 500’s total assets in 2020. This is a substantial increase from 1975’s figures, when intangible assets only accounted for 17% of the total assets, while tangible assets comprised the balance. The article noted that the explosion of intangible assets shows “that there is value to companies’ intellectual property (“IP”),” with patents holding the potential to be “far more valuable than physical assets” because they can offer businesses a competitive advantage (https://ibn.fm/WEEx9).

For its part, Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, looks at the value of its growing patent portfolio not only from a commercialization perspective but also from an IP protection standpoint. As CEO Chris Bunka put it in his 2024 letter to shareholders, “Those patents, when granted, can form the foundation upon which future commercial relationships are built” (https://ibn.fm/pQgX8).

The company recently received three new patents in the European Union (“E.U.”), Canada, and the United States (https://ibn.fm/SIK8w). In the EU, Lexaria received a newly granted patent in its patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. This patent is validated in Austria, the Czech Republic, France, the U.K., Germany, Italy, Poland, Spain, Sweden, and Switzerland. It is the company’s second patent in this family, following receipt of the first patent in Canada.

In Canada, Lexaria received a new patent granted in patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. It is the company’s fourth granted patent in this patent family and follows the receipt of a patent-granted status in the U.S., Australia, and Japan. Across the border in the U.S., Lexaria received its fourth granted U.S. patent in the patent family #24: Compositions and Methods for Treating Epilepsy.

The latter two patents granted in Canada and the U.S. build on the company’s research development initiatives and safeguard discoveries thereof. In 2021, Lexaria conducted research under its antiviral drug program, evidencing its patented DehydraTECH(TM) technology increased the delivery of five compounds from three antiviral classes into the bloodstream. The studies found that the drug-delivery improvement rates ranged between 42% and 204% (https://ibn.fm/dUCLC).

In addition, Lexaria in 2022 completed an animal seizure study that demonstrated that DehydraTECH-processed cannabidiol (“CBD”) resulted in enhanced seizure-inhibiting performance compared to Epidiolex(R), one of the world’s leading anti-seizure drugs. According to the company, the study’s results demonstrated the ability of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and to, in some instances, even surpass the performance of Epidiolex (https://ibn.fm/cZlYV).

The issuance of the latest three patents grows Lexaria’s patent portfolio to 46 granted patents worldwide. The company nonetheless continues to expect additional patents to be awarded in the future, given that it retains many valid patent applications throughout the world.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Ontario is renowned for world-class mining infrastructure and gold and copper deposits, with the world-class Timmins Gold Camp region hosting $400+ billion in gold resources
• Torr Metals is developing its 100% owned 261km² Filion Gold Project, ideally located adjacent to the Trans-Canada Highway 11 and northwest of Timmins, with all requisite mining infrastructure
• Late last year Torr conducted the first large-scale systematic soil program ever conducted in the project area, with39 of 318 humus samples returning highly anomalous values greater than 10 parts per billion (ppb) gold and13 exceeding 20 ppb Au, reaching a maximum of 1,320 ppb Au The largest undrilled soil anomaly measures 1200 meters in strike-length with a 250-meter width along-trend of historical channel sampling in limited outcrop that yielded 91.4 g/t Au over 0.3 meters
• Torr this month received a 3-year drill permit from the Ontario government, positioning the company for the first-ever drill program at Filion

Ontario’s mining history is practically synonymous with gold and copper. The Timmins gold rush and the Sudbury nickel irruptions are legendary, shaping the province’s economic landscape for over a century. But could Ontario’s best finds be yet to come? Torr Metals (TSX.V: TMET) thinks so.

While these established camps continue to produce, the surrounding underexplored areas with similar characteristics hold immense potential for new discoveries. 

Modern exploration techniques are powerful tools. Advanced geophysics and core drilling can peer deep beneath the surface, revealing hidden mineral deposits. These technologies, together with boots on the ground surface work can unlock the secrets of Ontario’s geology, pinpointing areas with the highest potential for harboring the next big gold or copper find.

Torr’s 100% owned 261km² Filion Gold Project is ideally situated adjacent to excellent infrastructure with direct road access from the Trans-Canada Highway 11, paralleled by the regional railway and provincial power grid, as well as the nearby town of Kapuskasing located ~30 km to the southeast. These significant factors not only result in lower costs to exploration but also provide opportunities for year-round operation potential.

Surrounding the Filion Gold Project are operations of the likes of Agnico Eagle, Alamos, Barrick, and the famous Timmins Gold Camp that cumulatively host an estimated 170 million ounces of gold worth some $400+ billion at current prices.

Gold deposits in this area often share similar geological features. Additionally, they’re often found nestled within major east-west fault zones, a setting that is also seen at Filion.

While neighbors’ mineralization is no guarantee, the prolific nature of the region is reason for immense optimism. Since acquiring the project in October 2023, Torr has moved quickly with the first modern exploration work on the land, including a systematic humus soil sampling program that was the first to test for broad mineralization along the gold endowed Filion Fault Zone; successfully confirming this potential in early 2024. Historical rock grab samples from this zone have also demonstrated the potential for high-grade mineralization, with values up to 9.1 g/t gold (Au) and channel sampling reportedly yielded 91.4 g/t Au over 0.3 meters.

Of the 318 humus soil samples, 39 showed greater than 10 parts per billion (ppb) gold with 13 exceeding 20 ppb Au, reaching a maximum of 1,320 ppb Au. The early work combined with historical data pointed towards the potential for significant mineralization; with Torr delineating six kilometer-scale gold soil anomalies that align with historical VLF-EM conductors across a 2.5-kilometer-wide corridor. More than 21 of the 28 known conductors have yet to be tested.

None of these areas have been tested by drilling. Torr is looking to change that.

The company announced on July 3 that it has received a three-year exploration permit from the Ontario government.

Malcolm Dorsey, President and CEO, commented, “The granting of this exploration permit opens up a tremendous opportunity for Torr to build on our promising work from late last year at the Filion Gold Project. We are very excited to further advance our exploration, especially after identifying extensive kilometer-scale gold soil anomalies that have yet to be drill tested along-trend of historical high-grade rock and channel samples.”

Dorsey added that the company is in the process of finalizing exploration plans and that he will keep investors updated on progress over the coming months.

In Ontario, the success of nearby mines serves as a powerful motivator. Existing infrastructure, skilled workforce, and established regulatory frameworks create a fertile ground for developing new discoveries. Ontario’s mining history may be a testament to its past riches, but it also paves the way for a future brimming with new opportunities to unearth the province’s next generation of mineral wealth.

For more information, visit the company’s website at www.TorrMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMET are available in the company’s newsroom at https://ibn.fm/TMET

• Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023
• The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases
• Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases

Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is continuing to make significant strides in the field of neurodegenerative diseases with its latest patent filings. The recent announcement is the filing of a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.

“The invention of a new solid form of our drug, buntanetap, and the subsequent patent filing represent groundbreaking milestones for our company,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis (https://ibn.fm/5vAuO). “This achievement will allow us not only to continue advancing our pipeline, but also to enhance the drug’s properties, ultimately providing greater benefits to our patients.”

Annovis is dedicated to developing unique treatments that can improve the lives of individuals suffering from neurodegenerative conditions. The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of these diseases. By addressing the root causes, Annovis aims to slow or even halt disease progression, offering hope to millions of patients worldwide.

Annovis Bio’s pipeline includes several promising candidates, with buntanetap being at the front of the line. The company’s research has shown that buntanetap can penetrate the blood-brain barrier effectively, allowing it to target the central nervous system directly. This capability is crucial for treating diseases like Alzheimer’s and Parkinson’s, where the brain is the primary site of pathology.

Michael Christie, Ph.D., Vice President of Process Chemistry for Annovis, said that as the company continues to advance its pipeline, securing manufacturing rights for new forms of buntanetap is vital. “This ensures we maintain control over the production process, protect our intellectual property, and continue our mission to deliver novel therapeutics for patients suffering from neurodegenerative disorders,” Christie added (https://ibn.fm/vH5kb).

In addition to buntanetap, Annovis is also exploring other therapeutic avenues, including the development of biomarkers for early diagnosis and disease monitoring. These efforts are aimed at providing a holistic approach to disease management, encompassing early detection, effective treatment, and ongoing monitoring.

Annovis’ mission extends beyond research and development; the company is also deeply committed to patient care. By collaborating with leading academic institutions and healthcare providers, Annovis ensures that its treatments are not only scientifically sound but also aligned with the needs of patients and clinicians.

The company has established numerous partnerships to facilitate clinical trials and gather real-world evidence on the efficacy of its treatments. These collaborations are critical for bringing new therapies to market and ensuring that they can make a tangible difference in patients’ lives.

The company’s creative approach to drug development and delivery sets it apart in the biotechnology industry. With its recent patent filings and ongoing research initiatives, Annovis holds a growing position in the fight against neurodegenerative diseases, a massive market.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels
LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

The third annual 420 Expo Cannabis Convention will be held Sept 13-15, 2024 at the New Jersey Convention & Exposition Center. The event is expected to bring over 15,000 cannabis enthusiasts together for three days of networking with cannabis industry traders from all over the country. In addition, the convention will feature seminars, panel discussions, food, music, after parties, and exciting giveaways.

The event will also showcase a first-of-its-kind contest for licensed cultivators across the Garden State to compete for the 420 Expo Cannabis Cup until Sunday, July 28. In addition, B-Real, lead rapper of the multi-platinum hip-hop group Cypress Hill, will be gracing the event as guest of honor.

420 Expo is a well-organized event, curated by a team of enthusiastic professionals with significant cannabis industry experience, encouraging the local cannabis community by bringing together investors, young and veteran cannabis vendors, creatives, and enthusiasts, on a dynamic common forum.

New Jersey became the fourteenth state to legalize marijuana completely, on February 22nd, 2021. Atlantic City has a flourishing cannabis market waiting to get tapped by industry experts. The 420 Expo will bring tremendous business and collaboration opportunities to the New Jersey cannabis community.

The 420 Expo offers an interactive forum for new cultivators to exhibit their products before cannabis traders, connoisseurs, and enthusiasts. More than 100 vendors covering dispensaries, CBD traders, food, clothing, art and more will be setting up display booths.

Experts will shed light on topics such as selecting the right cannabis strains, legal expungement, cannabis to help addiction and recovery, investments, and more, at the roundtables and discussion panels. The expo seminar will spotlight topics such as medical marijuana, networking in cannabis, social equity, legal rights, cooking with cannabis, and more.

Tickets for 420 Expo are now available for general admission, VIP access, and bucket list smoke sessions.

To learn more please visit https://ibn.fm/nG4mO

The Digital Assets Protection Webinar organized by Blockchain Legal Institute Inc. was held online on June 29, 2024, and covered the topic of safeguarding your Digital Assets & Legacy.

The event was attended by traders, entrepreneurs, shareholders, enthusiasts, businesses dealing in digital assets, and those who have a keen interest in the subject. Digital asset organizations and investors took to the platform to connect with experts and engage in important topics that guide the digital assets world. The speaker’s sessions were presided over by two esteemed dignitaries of the Digital assets realms, namely, Jacqueline Cooper, JD, CEO of the Blockchain Legal Institute, and Oge Anene, CEO of Beacon Consulting, Blockchain lawyer.

Pivotal topics covered in the conference include learning how to protect and manage their digital asset security. Experts shared insights on how organizations can secure access to their social media accounts, crypto, emails, and all digital assets. These invaluable insights by industry veterans will ensure businesses can create their digital assets legacy for secure access for generations to come.

For managing digital legacies, AI can play a crucial role in tasks like legacy planning, inventory creation, and so on. The conference saw meaningful discussions among attendees and expert tips by digital assets experts to leverage the latest technologies for creating legacies of digital assets. Further, they also spoke about the risks these technologies like AI can pose for digital legacies and ways to overcome the challenges. The latest legal policies for blockchain technology and digital assets were also important topics of discussion.

To know more, please visit https://ibn.fm/fE7WN

Join Us at the Sustainability Summit on October 23rd!

Don’t miss out on the opportunity to connect with thought leaders, industry experts, and fellow enthusiasts at our upcoming Sustainability Summit. Dive into insightful discussions, explore innovative solutions, and collaborate on shaping a sustainable future.

To know more, please visit https://ibn.fm/rUjOq

The highly anticipated Blockchain Futurist Conference, Canada’s Largest Web3 Event, is set to return for its sixth year to Toronto this August 13-14, 2024, with a focus on Artificial Intelligence as a core theme. This year’s event promises to offer sessions, panels, and sub-events centered around AI, highlighting how these technologies are transforming Web3 and reshaping our world. The dedicated AI segment is scheduled for Wednesday, August 14, 2024, and is accessible with all conference passes.

AI and Web3 technologies are rapidly converging to create a future that promises to revolutionize the digital landscape. AI’s ability to analyze vast amounts of data, and automate complex processes, complements Web3’s decentralized and transparent framework. This integration enables more secure, and equitable solutions across various sectors. 

At this year’s event, attendees can hear from top industry leaders in AI such as:

• Anthony Di Iorio, Founder, Ethereum, Decentral, Andiami
• Ben-Zion Benkhin, CEO, WOMBO
• Ashley Nandan, Google Canada, Startups
• Ari Juels, Chief Scientist, Chainlink Labs
• Christopher Johnson, Developer, Bad Idea AI
• Trevor Koverko, Co-Founder, Sapien
• JD Seraphine, CEO, Raiinmaker
• Breeze Liu, Founder & CEO, Alecto AI
• Christopher Obereder, Investor, Startup Chris Ventures
• Adam Benzine, Creator & Oscar(R)-Nominated Filmmaker

AI Futurist Conference will also host multiple sponsors dedicated to AI organizations, such as Inference Labs, a Gold Sponsor at this year’s event.

Inference Labs specializes in developing advanced infrastructure and products for AI on Web3. Their lab focuses on AI inference interoperating on the blockchain, an essential step for building a future where anyone can access AI without counterparty risk.

Ron Chan, Co-Founder of Inference Labs, and a visionary entrepreneur dedicated to pioneering the future of Decentralized AI had this to say:

“In all my years navigating tech cycles, I have never witnessed the level of developer interest in Artificial Intelligence that we see today. We’re at an inflection point where Internet traffic is roughly split 50/50 between humans and machines. I firmly believe that inference will soon become the dominant form of Internet traffic.”

With two decades of experience as a serial entrepreneur, Ron Chan has successfully navigated the ever-evolving tech industry, leading multiple technology and infrastructure startups to successful exits. His expertise spans architecting data centers, defense projects, and developing mission-critical civil aviation applications, showcasing his versatility and adeptness in managing complex, high-stakes ventures.

Futurist Conference will also host multiple sub-events and meetups for the AI community throughout the venue on both days. These include:

• Crypto x AI Book Signing: Ari Juels, Chief Scientist of Chainlink Labs and author of “The Oracle,” will discuss Crypto x Artificial Intelligence on the Main Stage, followed by a book signing
• AI Ethics Roundtable: A critical exploration of the ethical implications of AI and the transformative role of Web3 technologies
• AI Web3 & Robotics for Kids: A fun and interactive workshop for kids to learn about AI and Web3, with hands-on experience with robots
• Robots Live Onsite: Witness jaw-dropping innovations in action and experience the thrill of future technologies before your eyes

You can find all the events that are taking place at https://www.futuristconference.com/ai

Futurist Conference aspires to be more than just an event; it aims to create a future world within a conference, immersing attendees in the cutting-edge technologies that will shape tomorrow. By offering interactive experiences, and live demonstrations, the conference allows participants to see, feel, and engage with the latest advancements in AI, Web3, and beyond.

Futurist Conference is the perfect place for these industries to convene, providing a unique platform for thought leaders, innovators, and enthusiasts to explore the transformative potential of AI and Web3 technologies. Get ready to step into the future this August.

For more information and to buy tickets go to www.futuristconference.com.

For media inquiries please contact laura@untraceableinc.com.

For sponsorship inquiries please contact events@untraceableinc.com

• GEMXX recently announced the addition of Ali S. Abood to the board of its primary investment target, Latin Energy Partners (“LEP”)
• The company signed in early June a definitive agreement with LEP to drill four test wells in a highly promising geological formation in Latin America
• GEMXX and LEP are joining forces to fully harness the potential of two target basins estimated to hold more than 1 billion barrels each of recoverable oil
• The strategic addition of Mr. Abood to LEP’s board aligns with its commitment to strengthening its investment portfolio and expanding its influence in the global energy sector
• Mr. Abood brings a wealth of experience in international business, finance, and consultancy, having held senior directorships and advisory roles in multiple multinational corporations and done consultancy work for defense, engineering, and technology firms

GEMXX (OTC: GEMZ), a mine-to-market gold, gemstone, and jewelry producer with global reach, earlier this month signed a definitive agreement with Latin America Partners (“LEP”), an emerging leader and an independent E&P company involved in exploring significant hydrocarbon reserves in Latin America. The agreement kickstarted a collaboration to drill four test wells in a highly promising geological formation in Latin America, representing a significant milestone in the company’s expansion into the energy sector (https://ibn.fm/u6FWY).

LEP is guided by Dinesh Kumar Sarraf, the Chairman of the Board. The former Chairman and Managing Director of India’s premier E&P company, Oil and Natural Gas Corporation Ltd (“ONGC”), Mr. Sarraf is leveraging his extensive experience and strategic acumen to guide LEP toward identifying and developing 500-million-barrel (giant) and 3-billion+-barrel (super-giant) oil fields in Latin America. He leads a team of distinguished energy industry experts who, for decades, have been actively involved in global oil and gas exploration. This team has since expanded following a recent strategic addition.

As GEMXX announced in a recent news release, Ali S. Abood has joined the board of Latin Energy Partners (https://ibn.fm/pCvCK). The addition, GEMXX notes, aligns with its commitment to strengthening its investment portfolio and expanding its influence in the global energy sector.

“We are thrilled to announce Ali S. Abood has joined the board of Latin America Partners,” said Richard Clowater, CEO of GEMXX. “His extensive experience and proven track record in securing significant business relationships and funding will be invaluable as we continue to expand our investments in the energy sector. We are confident that Mr. Abood’s leadership and insights will drive substantial growth and success for Latin Energy Partners.”

Mr. Abood brings a wealth of experience in international business, finance, and consultancy. He has held senior directorships and advisory roles in multiple multinational corporations operating in a myriad of sectors, including mining, energy, commodity trading, and financial services. Notable roles include key positions at Esso (Exxon) and the National Commercial Bank of Saudi Arabia. He has also consulted for defense, engineering, and technology firms.

Mr. Abood is particularly known for his negotiation skills and high-level political and senior business contacts in the Middle East, Africa, and around the world. He boasts an entrepreneurial spirit and employs innovative marketing strategies that have seen him consistently secure substantial business deals for his clients. Mr. Abood is an expert in arranging funding through international government credit agencies and syndicated loans; this expertise has been crucial to facilitating major business transactions. As a result, GEMXX and its primary investment target, LEP, believe he is well-positioned to contribute to LEP’s strategic growth and success, a belief that Mr. Abood also holds.

“My extensive experience in international business and finance, particularly in the energy sector, has prepared me well for this exciting role. No other onshore oil blocks have this multi-billion-barrel potential. I look forward to leveraging my expertise to secure key business relationships and funding opportunities that will drive Latin Energy Partners to new heights,” conveyed Mr. Abood.

The collective experience of the team at LEP will be crucial in ensuring the success of the venture with GEMXX, which is expected to span the initial drilling phase through to potential full-scale production. According to GEMXX, preliminary explorations in two target basins have presented promising results. In particular, the results have revealed extensive sedimentary deposits perfect for successful oil and gas systems, with estimates suggesting these basins may hold more than 1 billion barrels each of recoverable oil. The estimates position GEMXX and LEP to establish a footprint in the global oil and gas market.

“We are eager to combine our expertise to fully harness the potential of these promising basins,” commented Clowater in a May 14 news release announcing the partnership with LEP (https://ibn.fm/Yi90w).

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• An overwhelming share of U.S. adults say marijuana should be legal for medical or recreational use, reports Pew Research Center
• The U.S. attorney general has submitted official notice to begin the process of moving marijuana from a Schedule 1 to Schedule 3 drug under the Controlled Substances Act
• MedCana is committed to building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts

With a significant majority of Americans supporting cannabis use and the U.S. government on the verge of changing the status of the substance under the Controlled Substances Act (“CSA”), Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is positioning itself for marked growth and success in the coming months. The company’s goal is to be the world’s premier resource for pharmaceutical cannabis products.

“As more states pass laws legalizing marijuana for recreational use, Americans continue to favor legalization of both medical and recreational use of the drug,” revealed a recent Pew Research Center survey (https://ibn.fm/OaWc1). “An overwhelming share of U.S. adults (88%) say marijuana should be legal for medical or recreational use.

“Nearly six in ten Americans (57%) say that marijuana should be legal for medical and recreational purposes, while roughly a third (32%) say that marijuana should be legal for medical use only,” the report continued. “Just 11% of Americans say that the drug should not be legal at all.”

After many years, the federal government is seemingly catching up to public opinion. In May the Justice Department announced that the attorney general had submitted official notice to begin the process of considering moving marijuana from a Schedule 1 to Schedule 3 drug under the CSA (https://ibn.fm/BE54W).

“Marijuana has been classified as a Schedule 1 drug since Congress enacted the CSA in 1970,” the announcement noted. “On Oct. 6, 2022, President Biden asked the attorney general and the secretary of Health and Human Services (‘HHS’) to launch a scientific review of how marijuana is scheduled under federal law. After receiving HHS’s recommendations last August, the attorney general sought the legal advice of the Justice Department’s Office of Legal Counsel (‘OLC’) on questions relevant to this rulemaking. In light of HHS’s medical and scientific determinations, and OLC’s legal advice, the attorney general exercised his authority under the law to initiate the rulemaking process to transfer marijuana to Schedule 3.”

The process to make the change includes several steps, including a public comment period and final judicial review. “Still, the reclassification of cannabis would mark a new era in America’s often contradictory relationship with a substance already legalized in one form or another in more than half the states,” stated an article in The Week (https://ibn.fm/ryFIL).

The Week noted that perhaps the most significant change reclassification would bring would be increasing governmental ability to conduct further research into the health benefits of cannabis. The article stated that “reclassification also means the government acknowledges cannabis, like all other Schedule 3 substances, has an ‘accepted medical use and may lawfully be dispensed by prescription,’ the Congressional Research Service said. However, any such prescriptions must be approved by the Food and Drug Administration.

“Beyond expanding and easing access to federal research opportunities, reclassifying cannabis will have a major impact on the booming — but still legally murky — marijuana industry as a whole,” the article observed.

With these looming changes as a backdrop, MedCana’s commitment to building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world is perfectly timed. Committed to absolute integrity, sustainability and social responsibility, MedCana is a holding company focused on developing companies in the agricultural-technology and the cannabis industries. As MedCana moves forward with its expansion plans, the company remains committed to delivering on its promise of building a solid foundation for future growth of its holdings.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://ibn.fm/SFWJ